search
Back to results

Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition

Primary Purpose

Healthy

Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Sirolimus
Sponsored by
Dr. Reddy's Laboratories Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

i. Provide written informed consent

ii. Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive) weighing at least 50 kg

iii. Having a body mass index between 18.0 and 24.9 (both inclusive), calculated as weight in Kg/height in m2

iv. Must be of normal health as determined by medical history, physical examination and laboratory investigation performed within 28 days prior to the commencement of the study. (Laboratory values must be within normal limits or considered by the physician / investigator to be of no clinical significance)

v. Female Subjects

  • Of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence
  • Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)

Exclusion Criteria:

i. Incapable of understanding the informed consent

ii. Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg

iii. Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg

iv. Oral temperature is below 95.0°F or above 98.6°F

v. Pulse rate below 50/min or above 100/min

vi. History of hypersensitivity or idiosyncratic reaction to investigational drug product or any other related drugs

vii. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function

viii. Consumption of grapefruit for the past ten days prior to the check-in, in each period

ix. Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking during sample collection period

x. Habit of alcoholism and difficulty in abstaining from alcohol during the sample collection period

xi. Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee, chocolates and cola drinks) during the sample collection period

xii. Intake of over the counter (OTC) or prescribed medications and enzyme modifying medication or systemic medication for the last 30 days before dosing

xiii. Clinically significant abnormalities and / or with significant diseases

xiv. Confirmed positive in alcohol screening

xv. Confirmed positive in selected drug of abuse

xvi. Participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study

xvii. Confirmed positive in urine pregnancy test

xviii. Female detected to be pregnant, breast feeding or who is likely to become pregnant during the study

Sites / Locations

  • Bioserve Clinical Research Pvt. Ltd

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Sirolimus tablets 2 mg

Rapamune

Arm Description

Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited

Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia

Outcomes

Primary Outcome Measures

Area under curve (AUC)

Secondary Outcome Measures

Full Information

First Posted
November 18, 2014
Last Updated
November 19, 2014
Sponsor
Dr. Reddy's Laboratories Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT02296762
Brief Title
Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition
Official Title
Open Label, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Sirolimus Tablets 2 mg Under Fed Condition
Study Type
Interventional

2. Study Status

Record Verification Date
March 2010
Overall Recruitment Status
Completed
Study Start Date
February 2010 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
February 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dr. Reddy's Laboratories Limited

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is to assess the Sirolimus Tablets 2 mg of Dr. Reddy's Laboratories Limited, India and Rapamune® (Sirolimus) tablets 2 mg of Wyeth Laboratories, Philadelphia in healthy, adult,human subjects under Fed conditions.
Detailed Description
Open label, randomized, two-treatment, two-period, two-sequence, cross over, single dose, oral bioequivalence study of Sirolimus tablets 2 mg under Fed conditions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sirolimus tablets 2 mg
Arm Type
Experimental
Arm Description
Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
Arm Title
Rapamune
Arm Type
Active Comparator
Arm Description
Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
Intervention Type
Drug
Intervention Name(s)
Sirolimus
Other Intervention Name(s)
Rapamune
Intervention Description
Sirolimus tablets 2 mg
Primary Outcome Measure Information:
Title
Area under curve (AUC)
Time Frame
predose (0.00) (0.00) and 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.25, 3.50, 3.75, 4.00, 4.50, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours post-dose.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: i. Provide written informed consent ii. Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive) weighing at least 50 kg iii. Having a body mass index between 18.0 and 24.9 (both inclusive), calculated as weight in Kg/height in m2 iv. Must be of normal health as determined by medical history, physical examination and laboratory investigation performed within 28 days prior to the commencement of the study. (Laboratory values must be within normal limits or considered by the physician / investigator to be of no clinical significance) v. Female Subjects Of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject) Exclusion Criteria: i. Incapable of understanding the informed consent ii. Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg iii. Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg iv. Oral temperature is below 95.0°F or above 98.6°F v. Pulse rate below 50/min or above 100/min vi. History of hypersensitivity or idiosyncratic reaction to investigational drug product or any other related drugs vii. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function viii. Consumption of grapefruit for the past ten days prior to the check-in, in each period ix. Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking during sample collection period x. Habit of alcoholism and difficulty in abstaining from alcohol during the sample collection period xi. Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee, chocolates and cola drinks) during the sample collection period xii. Intake of over the counter (OTC) or prescribed medications and enzyme modifying medication or systemic medication for the last 30 days before dosing xiii. Clinically significant abnormalities and / or with significant diseases xiv. Confirmed positive in alcohol screening xv. Confirmed positive in selected drug of abuse xvi. Participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study xvii. Confirmed positive in urine pregnancy test xviii. Female detected to be pregnant, breast feeding or who is likely to become pregnant during the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr. Dwarakanath, MBBS
Organizational Affiliation
Bioserve Clinical Research Pvt Ltd
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bioserve Clinical Research Pvt. Ltd
City
Balanagar, Hyderabad
State/Province
Andhra Pradesh
ZIP/Postal Code
500 037
Country
India

12. IPD Sharing Statement

Learn more about this trial

Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition

We'll reach out to this number within 24 hrs